ClinicalTrials.gg
TerminatedNCT03707028Updated Apr 11, 2022

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

A Phase 1/2 interventional study of Rivoceranib and Paclitaxel in Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Elevar Therapeutics. Terminated at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Elevar Therapeutics · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Terminated after completion of Part 1 due to a change in research plan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies testing apatinib in Stomach Neoplasms — 14 open to participants now, 15 under way, 4 of them phase 3. apatinib · Stomach Neoplasms.

Enrollment
54th of 57
12 · median 47
Started
2018
with 6 others
Phase 1/2
3 of 57
none open now
Registered
30th of 57
by date
Lead sponsor
2 of 57
Elevar Therapeutics

Among the 57 studies testing apatinib in Stomach Neoplasms, this one is the 54th largest by enrollment, is one of 7 that started in 2018, is one of 3 in phase 1/2, and was the 30th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

14 of the 57 studies testing apatinib in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing apatinib in Stomach Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase I/IIa study designed to determine the recommended Phase 2 dose (RP2D) and the safety and tolerability profile along with preliminary signs of efficacy of rivoceranib in combination with paclitaxel as a second-line therapy in advanced, recurrent and/or metastatic gastric or gastroesophageal junction cancer. This study will also characterize the pharmacokinetic (PK) parameters of rivoceranib and paclitaxel when given in combination.

Read the detailed description

Primary Phase I Objectives

  • To determine the RP2D dose of rivoceranib in combination with paclitaxel.

Primary Phase II Objectives

  • To determine clinical activity of the combination of rivoceranib and paclitaxel.

Secondary Phase I Objectives

  • To evaluate the PK of rivoceranib and paclitaxel when given in combination.
  • To assess the efficacy of rivoceranib in combination with paclitaxel.

Secondary Phase II Objectives

  • To assess the efficacy of rivoceranib in combination with paclitaxel.
  • To assess the safety and tolerability of rivoceranib in combination with paclitaxel.
  • To assess the PK of rivoceranib and paclitaxel when given in combination.
03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with documented locally advanced unresectable or gastric or gastroesophageal junction cancer to or relapsing after platinum and fluoropyrimidine containing chemotherapy (with or without trastuzumab) with an indication for therapy with paclitaxel and an antiangiogenic agent. If disease progression occurs during or within 6 months after completion of any chemotherapy, this therapy is considered a first-line chemotherapy for participant eligibility.
  2. Participants who have provided tumor tissue prior to initiation of first-line therapy and have provided or can provide tumor tissue prior to screening in this study. This will be optional for Phase I participants. Tumor tissue must not have been irradiated.
  3. Participants who have at least 1 as defined by v1.1. This will be optional for Phase I participants.
  4. Adequate bone marrow, renal, and liver function evidenced by:

    1. Hematologic: of ≥1,500/cubic millimeter (mm\^3), count of ≥ 1,00,000/mm \^3, and of ≥9.0 grams (g)/deciliter (dL). Transfusion of platelets or red blood cells to meet the inclusion criteria within 2 weeks of screening is not allowed.
    2. Adequate renal function, defined as meeting any 1 of the following criteria:

    i. Serum creatinine \<1.5 × (ULN). ii. based on the Cockcroft-Gault estimate ≥50 milliliters per minute (mL/min) or creatinine clearance based on urine collection (12 or 24 hours) ≥50 mL/min.

    iii. In addition, urinary protein should be \<2+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24 hour urine or urine protein/creatinine ratio must be collected and must demonstrate \<2 g of protein in 24 hours.

    c) Hepatic: Serum \<1.5 × ULN, aspartate and ≤3.0 × ULN (≤5.0 × UNL, if with liver metastases). If liver and/or bone metastases alkaline phosphatase ≤5 × ULN.

  5. Blood coagulation tests: and international normalized ratio ≤1.5 × ULN.
  6. (ECOG) performance status 0 or 1.
  7. Estimated of at least 12 weeks.
  8. Ability to swallow the study drug without chewing, breaking, crushing, opening or otherwise altering the product formulation. If vomiting occurs, the dose will not be replaced. Antiemetics must be used at efficacious doses.
  9. No major gastrointestinal disease (e.g., chronic diarrheal disease) or intestinal surgery that can jeopardize drug absorption.

Exclusion criteria

Exclusion Criteria

  1. Prior use of taxane (paclitaxel or docetaxel) or any for therapy with paclitaxel.
  2. Previous treatment with rivoceranib or any other systemic therapy with a vascular endothelial growth factor (VEGF) pathway inhibitor.
  3. Known to rivoceranib or any component of its formulation or history of severe adverse events, including uncontrolled hypertension or other common anti-angiogenesis drug class effects during prior exposure to vascular inhibitors.
  4. Any unresolved toxicity Grade >1 (except alopecia) from previous anticancer therapy (including radiotherapy).
  5. Has history of another within 2 years prior to screening. Participants with the following are eligible for this study if, in the opinion of the investigator, they do not pose a significant risk to :

    1. Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (Tis).
    2. Curatively treated cervical carcinoma in situ.
    3. Thyroid papillary cancer with prior treatment.
    4. Carcinoma of the skin without melanomatous features.
    5. Prostate cancer which has been surgically or medically treated and not likely to recur within 2 years.
  6. Known or other central nervous system that is either symptomatic or untreated. Metastases that have been treated by complete resection and/or radiotherapy demonstrating stability or improvement are not an exclusion criterion provided they are stable as shown by computed tomographic scan at least 4 weeks before screening without evidence of cerebral edema. Participants on stable dose of or anticonvulsants are permitted.
  7. Has received prior anticancer therapy within 3 weeks before Cycle 1 Day 1. Traditional herbal remedies with anti-infective, immune stimulating, or anticancer properties are not allowed from screening throughout the entire period of study participation.
  8. Current or recent (within 10 days of Cycle 1 Day 1) use of full dose oral or parenteral anticoagulants or other thrombolytic agents for therapeutic (as opposed to prophylactic) purposes, clinically serious non-healing wounds, or incompletely healed bone fracture. A maximum dose of 325 milligrams (mg)/day of aspirin is allowed.
  9. Participants who had therapeutic paracentesis of ascites (>1 liter [L]) within the 2 months prior to starting study treatment or who, in the opinion of the investigator, will likely need therapeutic paracentesis of ascites (>1L) within 2 months of Cycle 1 Day 1.
  10. Concomitant treatment with strong inhibitors or inducers of , CYP2C9, and CYP2C19.
  11. Active bacterial infections (including tuberculosis and syphilis) requiring systemic antibiotic therapy.
  12. Known history of infection.
  13. Active or C infection or chronic hepatitis B or C infection requiring treatment with antiviral therapy or prophylactic antiviral therapy; unless evidence of viral suppression has been documented and the participant will remain on appropriate antiviral therapy throughout the study.
  14. Stage B and C liver function impairment.
  15. Pregnant or breastfeeding women. Participants unwilling to comply with requirements will not be eligible.
  16. History of uncontrolled hypertension (blood pressure ≥140/90 mmHg and change in antihypertensive medication within 7 days prior to screening) that is not well managed by medication and the risk of which may be precipitated by a VEGF inhibitor therapy. History of hypertensive crisis, and hypertensive encephalopathy.
  17. Participants who have a known history of symptomatic congestive heart failure ( III to IV), symptomatic or poorly controlled cardiac arrhythmia, complete left bundle branch block, bifascicular block, or any ST segment and/or T wave abnormalities, interval by Fredericia (QTcF) > 450 msec for males or QTcF > 470 milliseconds (msec) for females prior to screening.
  18. History of bleeding diathesis or clinically significant bleeding within 14 days prior to Cycle 1 Day 1. This includes a history of gastrointestinal bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3 months prior to Cycle 1 Day 1 that, in the investigator's opinion, may place the participant at risk of side effects from anti-angiogenesis products.
  19. History of clinically significant thrombosis (bleeding or clotting disorder) within the past 3 months prior to Cycle 1 Day 1 that, in the investigator's opinion, may place the participant at risk of side effects from anti-angiogenesis products.
  20. History of other significant cardiovascular diseases or vascular diseases within the last 6 months prior to screening (e.g., myocardial infarction or unstable angina pectoris, stroke or , or significant peripheral vascular diseases) that, in the investigator's opinion, may pose a risk to the participant on vascular endothelial growth factor receptors (VEGFR) inhibitor therapy.
  21. History of clinically significant glomerulonephritis, -proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies.
  22. Psychological, familial, sociological, or geographical conditions including drug or alcohol abuse that do not permit compliance with the study participation or evaluation of the study results.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Rivoceranib with Paclitaxel

    Participants will receive oral daily doses of rivoceranib per 28-day cycle (as its mesylate salt) with a fixed dose of paclitaxel given intravenously on Day 1, Day 8, and Day 15 of the 28-day cycle.

    Drug: Rivoceranib · Drug: Paclitaxel

Interventions

  • Film-coated tablet

    Also known as: Apatinib

  • Solution administered intravenously

    Also known as: Taxol

06

What researchers measure

Primary outcomes

  1. Phase I: Incidence of Dose-Limiting Toxicities (DLT) During Cycle 1

    The number and proportion of participants experiencing DLTs will be reported by dose level, based on DLT observations during Cycle 1. Each Cycle is 28 days.

    Time frame: Cycle 1 (first 28 days)

  2. Phase I: Number of Participants Reporting Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a participant or participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, or important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the other outcomes listed above.

    Time frame: Up to 24 months

  3. Phase II: Objective Response Rate (ORR)

    ORR is the percentage of participants who achieve objective tumor response (complete response \[CR\] or partial response \[PR\]) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria for response.

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

Secondary outcomes

  1. Phase I: Maximum Observed Concentration (Cmax)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  2. Phase I: Time to Maximum Observed Concentration (tmax)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  3. Phase I: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC0-t)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  4. Phase I: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  5. Phase I: Terminal Half-life (t1/2)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  6. Phase I: Apparent Oral Plasma Clearance (CL/F)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  7. Phase I: Apparent Volume of Distribution (Vz/F)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  8. Phase I: Terminal Rate Constant (λz)

    Time frame: Day 1 & 15 of Cycle 1 (each cycle is 28 days)

  9. Phase I: ORR

    ORR by RECIST 1.1

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

  10. Phase I: Progression-free Survival (PFS)

    Defined as time from first dose of study drug (Cycle 1 Day 1) to the time of first documented disease progression or death due to any cause.

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

  11. Phase I: Overall survival (OS)

    OS is the time from first dose of study drug (Cycle 1 Day 1) to the time of death from any cause.

    Time frame: Ongoing assessment from enrollment until end of study, up to approximately 24 months

  12. Phase I: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants who achieve CR or PR and stable disease (SD) at ≥12 weeks.

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

  13. Phase I: Duration of Response

    Defined as the time from first documentation of (complete response or partial response) to the first documentation of progression.

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

  14. Phase II: PFS

    Defined as time from first dose of study drug (Cycle 1 Day 1) to the time of first documented disease progression or death due to any cause.

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

  15. Phase II: OS

    OS is the time from first dose of study drug (Cycle 1 Day 1) to the time of death from any cause.

    Time frame: Ongoing assessment from enrollment until end of study, up to approximately 24 months

  16. Phase II: DCR

    DCR is defined as the percentage of participants who achieve CR or PR and SD at ≥12 weeks.

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

  17. Phase II: Duration of Response

    Defined as the time from first documentation of (complete response or partial response) to the first documentation of progression.

    Time frame: Every other cycle (each cycle is 28 days) until end of study, assessed up to 24 months

  18. Phase II: Number of Participants With AEs and SAEs

    Adverse Events and Serious Adverse Events

    Time frame: Ongoing assessment from enrollment until end of study, approximately 24 months

  19. Phase II: Concentration at the End of the Dosage Interval (Ctrough)

    Ctrough is characterized at steady state after single and multiple cycles of treatment.

    Time frame: Ongoing assessment from enrollment until end of study, approximately 24 months

07

Study locations

1 site
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Aug 2021, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2018
First posted
Oct 16, 2018
StartActual
Oct 1, 2018
Primary completionActual
Aug 24, 2021
CompletionActual
Aug 24, 2021
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03707028
Lead sponsor
Elevar Therapeutics
Responsible party
Sponsor
First posted
Oct 16, 2018
Start date
Oct 1, 2018
Primary completion
Aug 24, 2021
Completion
Aug 24, 2021
Last update
Apr 11, 2022

Study contacts

Min-Hee Ryu, Dr.
principal investigator · Asan Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apatinib · Paclitaxel

Start the discussion